Next Article in Journal / Special Issue
The Marine Fungal Metabolite, AD0157, Inhibits Angiogenesis by Targeting the Akt Signaling Pathway
Previous Article in Journal
Holothurian Fucosylated Chondroitin Sulfate
Previous Article in Special Issue
Palmitic Acid and Ergosta-7,22-dien-3-ol Contribute to the Apoptotic Effect and Cell Cycle Arrest of an Extract from Marthasterias glacialis L. in Neuroblastoma Cells
Mar. Drugs 2014, 12(1), 255-278; doi:10.3390/md12010255
Review

Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development

*  and
Natural Products Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory, P.O. Box B, Frederick, MD 21702, USA
The opinions expressed in this review are those of the authors, not necessarily those of the US Government.
* Author to whom correspondence should be addressed.
Received: 5 December 2013 / Revised: 17 December 2013 / Accepted: 7 January 2014 / Published: 14 January 2014
(This article belongs to the Special Issue Marine Compounds and Cancer)
View Full-Text   |   Download PDF [501 KB, uploaded 24 February 2015]   |   Browse Figures

Abstract

The marine habitat has produced a significant number of very potent marine-derived agents that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of cases, in both in vivo murine models and in humans. Although many agents have entered clinical trials in cancer, to date, only Cytarabine, Yondelis® (ET743), Eribulin (a synthetic derivative based on the structure of halichondrin B), and the dolastatin 10 derivative, monomethylauristatin E (MMAE or vedotin) as a warhead, have been approved for use in humans (Adcetris®). In this review, we show the compounds derived from marine sources that are currently in clinical trials against cancer. We have included brief discussions of the approved agents, where they are in trials to extend their initial approved activity (a common practice once an agent is approved), and have also included an extensive discussion of the use of auristatin derivatives as warheads, plus an area that has rarely been covered, the use of marine-derived agents to ameliorate the pain from cancers in humans, and to act as an adjuvant in immunological therapies.
Keywords: Antibody Drug Conjugates (ADCs); marine antitumor agents; clinical trials; approved antitumor agents Antibody Drug Conjugates (ADCs); marine antitumor agents; clinical trials; approved antitumor agents
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Newman, D.J.; Cragg, G.M. Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar. Drugs 2014, 12, 255-278.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here

Comments

Cited By

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert